Hannah Green
Life Sciences reporter at Boston Business Journal
Life sciences reporter @BosBizJournal | [email protected] | Alum: @GBHNews @DJNF @COMatBU @IfillCollege | WMass raised | Runs for fun
Articles
-
1 week ago |
bizjournals.com | Hannah Green
In addition to news coming out of the BIO International Convention, this week Isomorphic announced the opening of its Cambridge office, a Harvard lab landed funding from a Turkish private equity group, and Crescent Biopharma hit Nasdaq.
-
1 week ago |
nbcboston.com | Hannah Green
Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow Cambridge biotech Biogen Inc. Sage announced on Monday it would be bought out by Supernus Pharmaceuticals Inc., a Maryland-based biopharma that develops and commercializes treatments for central nervous system diseases. Stream NBC10 Boston news for free, 24/7, wherever you are. More on this story from Boston Business Journal
-
2 weeks ago |
nbcboston.com | Hannah Green
BioNTech SE is acquiring a vaccine developer with its U.S. headquarters in Boston that had sued it just a few years ago over its COVID-19 patents. CureVac NV, which is based in Germany but has U.S. headquarters at 250 Summer St., is being acquired in a deal valued at $1.25 billion by BioNTech, according to a deal announcement on Thursday morning. Stream NBC10 Boston news for free, 24/7, wherever you are. More on this story from Boston Business Journal
-
2 weeks ago |
nbcboston.com | Hannah Green
Over the last several decades, Massachusetts has built itself into the No. 1 biotech hub in the world. The numbers demonstrate the state’s dominance in life sciences. Nearly $7.9 billion in venture capital flowed to Bay State biotechs in 2024. Eighteen of the top 20 pharma companies have a presence in Massachusetts. And the state routinely brings in more NIH funding per capita than any other state. Stream NBC10 Boston news for free, 24/7, wherever you are.
-
2 weeks ago |
nbcboston.com | Hannah Green
Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island. The Boston drugmaker said in a new Worker Adjustment And Retraining Notification that it is laying off 125 employees who work in Providence at 225 Carolina Avenue, 63 Baker Street and 75 Baker Street, which make up one campus. The cuts are expected to begin around August 5. Stream NBC10 Boston news for free, 24/7, wherever you are. More on this story from Boston Business Journal
Journalists covering the same region
Irene Rotondo
Reporter at MassLive.com
Irene Rotondo primarily covers news in Boston, Massachusetts, United States and surrounding areas including Cambridge and Quincy.
Roberto Scalese
Senior Editor, Digital at WBUR-FM (Boston, MA)
Roberto Scalese primarily covers news in Boston, Massachusetts, United States and surrounding areas including Framingham.
Cailin Loesch
Host at Double Talk
Senior Editor at Scholastic
Cailin Loesch primarily covers news in the Greater Boston area including Cambridge and surrounding suburbs in Massachusetts, United States.
Solangi Sosa
Anchor at WNEU-TV (Boston, MA)
Solangi Sosa primarily covers news in the Greater Boston area including Cambridge, Somerville, and surrounding regions in Massachusetts, United States.
Lauren Young
Producer at WPRI-TV (Providence, RI)
Lauren Young primarily covers news in the Greater Boston area including Cambridge and surrounding suburbs in Massachusetts, United States.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 1K
- Tweets
- 1K
- DMs Open
- No
Scoop: Lyndra Therapeutics, a drug developer that spun out of the lab of MIT professor Bob Langer in 2015, is winding down operations after running out cash. https://t.co/yPdJXjW4aZ
BREAKING: Sage Therapeutics is rejecting the unsolicited acquisition offer from Biogen — but, it's open to other deals. https://t.co/hydtbnJvQn
The Massachusetts Life Sciences Center will no longer offer its angel investor tax credit, a program designed to drive early-stage investment in life science startups. Economic Development Secretary Yvonne Hao told the @BosBizJournal why it was cut. https://t.co/mobS1yrRff